World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt

February 16, 2024 updated by: Nasser Institute For Research and Treatment

Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt

Objectives: identify and recognize clinical Characteristics, Pathophysiology, and management of a group of patients with rhino Rhino-Orbito-Cerebral Mucormycosis infection associated with Covid 19 viral infection

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt
        • Omar Elmonofy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • all patients with mucormycosis post covid 19

Exclusion Criteria:

  • The patient not suffered from covid 19

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17 years
Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17 years eighteen patients presented with COVID 19 and seventeen patients presented to our hospital post healing with history of using large doses of systemic corticosteroids. patients were managed by aggressive surgical debridement, antifungal drugs Amphotericin B and adjunctive treatment like local irrigation with amphotericin B and hyperbaric oxygen according to systemic conditions of patients. Hyperbaric oxygen was used in five patients post-surgically. all investigations were done with mean values of blood glucose level, hemoglobin and WBC were noticeably abnormal. The degree of severity, length of stay, and mortality rate were significantly correlated with the severity of systemic predisposing factors
Procedure: debridment
resection of dead bone
Other Names:
  • medication
Experimental: Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17
Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17 years eighteen patients presented with COVID 19 and seventeen patients presented to our hospital post healing with history of using large doses of systemic corticosteroids. patients were managed by aggressive surgical debridement, antifungal drugs Amphotericin B and adjunctive treatment like local irrigation with amphotericin B and hyperbaric oxygen according to systemic conditions of patients. Hyperbaric oxygen was used in five patients post-surgically. all investigations were done with mean values of blood glucose level, hemoglobin and WBC were noticeably abnormal. The degree of severity, length of stay, and mortality rate were significantly correlated with the severity of systemic predisposing factors
Procedure: debridment
resection of dead bone
Other Names:
  • medication

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
35 patients suffering from mucormycosis infection post covid 19
Time Frame: 2 years
Ratio Scale. Visual Analog Score for pain Ratio Scale. Ratio Scale. ratio scale
2 years
25 patients were cured with comorbidity and 10 pateints died
Time Frame: 2 years
ordinal scale Visual Analog Score for pain
2 years
pain
Time Frame: two years
Visual Analog Score for pain
two years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual Analog Score for pain
Time Frame: 2years
pain
2years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nasser Institute For Research and Treatment

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 23, 2021

Primary Completion (Actual)

June 12, 2022

Study Completion (Actual)

August 21, 2023

Study Registration Dates

First Submitted

January 20, 2024

First Submitted That Met QC Criteria

February 16, 2024

First Posted (Actual)

February 20, 2024

Study Record Updates

Last Update Posted (Actual)

February 20, 2024

Last Update Submitted That Met QC Criteria

February 16, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Nasser institute

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on debridment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe